research & development
Enzymatica focuses on product development based on the tested and patented barrier technology used in the cold product ColdZyme.
The barrier in ColdZyme® consists of a transparent liquid solution including glycerol and enzymes from deep-sea cod. The main mechanism of action of the barrier is based on its ability to generate an osmotically active viscous solution (barrier or film) on the mucous membrane in the mouth/throat that adsorbs fluid. This fluid contains viruses. When applied to the mouth/throat, as in the case of ColdZyme, the viral presence declines, thereby facilitating a faster natural recovery from the common cold.
Enzymatica focuses on product development based on the tested and patented barrier technology used in the cold product ColdZyme. Strengthening the clinical documentation for ColdZyme is a key part of Enzymatica’s R&D activities.
Shorter duration of common colds for endurance athletes with ColdZyme® In a British investigator-initiated study conducted at the University of Kent, 123 elite athletes in endurance sports such as triathlon, marathon and cycling were randomized to treatment with ColdZyme® or to the control group.
Enzymatica’s scientific advisors are established, well-known researchers in fields such as upper respiratory tract infections. They assist Enzymatica in research-related issues, as well as assess and advise on future research and product opportunities.